Type-2 diabetes is an increasing public-health problem, both in terms of treating the condition itself, and in preventing complications. Optimising clinical outcomes depends on reducing HbA1C, as seen in the Quality and Outcomes Framework and in recommendations from NICE. The recommended first-line treatment is metformin, but poor adherence to this and other therapies potentially leads to worsening outcomes for patients.